The BETAMI-DANBLOCK Trial

22.7.2026

Talking Points

0:00

8:38

How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.

Weitere Episoden von „Talking Points“

The Evolut Low Risk Trial
4.11.2026
5:11
Michael J. Reardon and C. Michael Gibson discuss the 5-year outcomes of TAVR or SAVR in low-risk patients with AS.
The BHF PROTECT-TAVI Trial
14.10.2026
5:42
Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.
Verpasse keine Episode von “Talking Points” und abonniere ihn in der kostenlosen GetPodcast App.
The FAME 3 Trial
16.9.2026
9:02
William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
The TRILUMINATE Pivotal Trial
2.9.2026
8:04
Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.
The PRAGUE-25 Study
5.8.2026
7:57
Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
The BETAMI-DANBLOCK Trial
22.7.2026
8:38
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI
1.7.2026
1:33:28
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
The PROCTOR Trial
3.6.2026
8:35
Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
The SELUTION DeNovo Trial
20.5.2026
5:08
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
The VESALIUS-CV Trial
6.5.2026
7:21
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.

Weitere Episoden

Hol dir die ganze Welt der Podcasts mit der kostenlosen GetPodcast App.

Abonniere alle deine Lieblingspodcasts, höre Episoden auch offline und erhalte passende Empfehlungen für Podcasts, die dich wirklich interessieren.

Ein Unternehmen von

The BETAMI-DANBLOCK Trial

Talking Points

Weitere Episoden von „Talking Points“

The Evolut Low Risk Trial

The BHF PROTECT-TAVI Trial

The FAME 3 Trial

The TRILUMINATE Pivotal Trial

The PRAGUE-25 Study

The BETAMI-DANBLOCK Trial

New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI

The PROCTOR Trial

The SELUTION DeNovo Trial

The VESALIUS-CV Trial